Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial

Group 1 - Novo Nordisk's experimental obesity drug CagriSema did not meet the primary endpoint in a trial aimed at demonstrating non-inferiority to Eli Lilly's Tirzepatide in terms of body weight reduction [1] - The trial results indicate a setback for Novo Nordisk in the competitive obesity drug market, where Eli Lilly's Tirzepatide has shown strong performance [1] - This development may impact Novo Nordisk's market position and future growth prospects in the obesity treatment sector [1]